CYTOSORB

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses... CytoSorbents Europe GmbH, headquartered in Berlin, is a wholly owned subsidiary of CytoSorbents Corporation of Monmouth Junction, New Jersey, USA, where the CytoSorb product is manufactured. CytoSorb is the company's flagship product, backed by more than 30 patent families... CytoSorb is the only adsorber approved for a treatment time per device up to 24 hours. independently by the mode of operation or the blood flow to enhance the continuity and efficacy of the treatment.

Registration numbers: HRB 140433 B (W)

VAT numbers: DE283135831

Primary location: Berlin